Business
SK bioscience Initiates Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate
SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced the commencement of global Phase 1/2 clinical trials for its mRNA-based Japanese encephalitis vaccine candidate, GBP560.
About this update from Sk Bioscience Co.,ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"SK bioscience's first mRNA vaccine candidate enters Phase 1/2 clinical trials in Australia and New Zealand, with interim results expected by 2026","length":149,"tagName":"p"}]},{"val":[{"type":"text","content":"Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from CEPI","length":113,"tagName":"p"}]},{"val":[{"type":"text","content":"SK bioscience will expand its vaccine portfolio and secure global competitiveness by developing mRNA vaccines","length":109,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":371,"olType":false},{"type":"text","content":"SEONGNAM, South Korea, Feb. 25, 2025 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced the commencement of global Phase 1/2 clinical trials for its mRNA-based Japanese encephalitis vaccine candidate, GBP560.","length":313,"tagName":"p"},{"type":"image","alt":"SK bioscience L HOUSE manufacturing plant","displaySize":"","headline":null,"caption":"SK bioscience L HOUSE manufacturing plant","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":259,"url":"https://media.zenfs.com/en/prnewswire.com/fce3405fe345e0a6a247239f3aa64281"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8ObSZ9i9my5laCMRg6atkw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ1NjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/fce3405fe345e0a6a247239f3aa64281","width":400,"height":259}},"href":"https://mma.prnewswire.com/media/2627183/SK_bioscience_L_HOUSE_manufacturing_plant.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"SK bioscience's development of vaccine for Japanese encephalitis could not only help to protect against Japanese Encephalitis but also pave the way to the development of an mRNA technology that could be potentially adapted in a matter of weeks to develop a vaccine against a novel as-yet-identified infectious disease 'Disease X'.","length":342,"tagName":"p"},{"type":"text","content":"This rapid response approach would support the '100 Day Mission', a global initiative spearheaded by the Coalition for Epidemic Preparedness Innovations (CEPI) and embraced by the G7, G20 and pharmaceutical companies to accelerate the development o...